Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01382940 · ClinicalTrials.gov registry record · Phase 4

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

A Phase 4 study of Rheumatoid Arthritis, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 4
Development phase
351
Enrollment target
20
Study locations

NCT01382940 is a Phase 4 study of Rheumatoid Arthritis that has completed, run by Hoffmann-La Roche. The registered enrollment target is 351 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01382940, a Phase 4 study of Rheumatoid Arthritis, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 4
Development phase
351 participants
Enrollment target
20
Study locations

Study Summary

This study was designed to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to biopharmaceuticals that treat diseases by interfering with tumor necrosis factor (anti-TNF therapies), and were receiving methotrexate therapy for more than eight weeks.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG methylprednisolone
  • DRUG rituximab
  • DRUG methotrexate
  • DRUG acetaminophen
  • DRUG antihistamine

Study Locations (20)

California

  • Medvin Clinical Research - Covina
  • Triwest Research Associates - La Mesa
  • Medvin Clinical Research - Los Angeles
  • Brigid Freyne-Private Practice; Internal Medicine, Rheum - Murrieta
  • Desert Medical Advances; Rheumatology - Palm Desert
  • San Diego Arthritis Med Clnc - San Diego
  • Pacific Arthritis Ctr Med Grp - Santa Maria
  • Inland Rheumatology; Clinical Trials, Inc. - Upland
  • Medvin Clinical Research - Whittier

Arizona

  • ArthroCare, Arthritis Care; and Research P.C. - Gilbert
  • Valley Arthritis Care - Phoenix
  • Catalina Pointe Rheumatology - Tucson

Alabama

  • Uni Of Alabama,Birmingham; Medicine - Rheumatology - Birmingham
  • Clnical & Translational Reseach Center for Alabama, PC - Tuscaloosa

Colorado

  • Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs - Colorado Springs
  • Denver Arthritis Clinic - Denver

Connecticut

  • Rheum & Internal Med Assoc-Bri - Bridgeport
  • Arthritis & Osteoporosis Center Pc - Hamden

Delaware

  • Rheumatolgy Consultants of Deleware - Lewes
  • Javed Rheumatology Associates, Inc. - Newark

Trial Details

FieldValue
Enrollment Target 351 participants
Start Date 2011-07-26
Est. Completion 2013-01-06
Phase Phase 4

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01382940

The ClinicalTrials.gov registry entry for NCT01382940 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (93% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 5 interventions - of which methylprednisolone is the first listed.

NCT01382940 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT01382940 about?

NCT01382940 is a clinical study titled "A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis". This study was designed to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to biopharmaceuticals that treat diseases by interfering with tumor necrosis factor (anti-TNF therapies...

What is the current status of trial NCT01382940?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 351 participants. The study started on 2011-07-26. Estimated completion is 2013-01-06.

What conditions does trial NCT01382940 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01382940?

The interventions under investigation include: methylprednisolone (DRUG), rituximab (DRUG), methotrexate (DRUG), acetaminophen (DRUG), antihistamine (DRUG).

Who is sponsoring clinical trial NCT01382940?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01382940 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.